Editorial

Consideration of Subcutaneous Immunoglobulin Replacement Therapy in Humoral Immunodeficiency Patients

Authors: Jason K. Lee, MD, FRCPC, Stephen D. Betschel, MD, FRCPC

Abstract

Antibody-related defects or humoral primary immunodeficiencies account for 65–70% of all primary immunodeficiencies.1–3Common variable immunodeficiency (CVID) is the clinically relevant primary immunodeficiency most commonly encountered. CVID is a heterogeneous group of disorders characterized by hypogammaglobulinemia, increased susceptibility to recurrent pyogenic infections,4 autoimmunity,5–7 noncaseating sarcoid like granulomas,8 gastrointestinal disease (diarrhea, lambliasis, nodular lymphatic hyperplasia),9 and neoplastic diseases.2,3Appropriate diagnosis and management of CVID patients will have a significant effect on morbidity and mortality.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Cunningham-Rundles C. Lung disease, antibodies and other unresolved issues in immune globulin therapy for antibody deficiency. Clin Exp Immunol 2009;157(suppl 1):12–16.
 
2. Park MA, Li JT, Hagan JB, et al. Common variable immunodeficiency: a new look at an old disease. Lancet 2008;372:489–502.
 
3. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999;92:34–48.
 
4. Busse PJ, Farzan S, Cunningham-Rundles C. Pulmonary complications of common variable immunodeficiency. Ann Allergy Asthma Immunol 2007;98:1–8; quiz 8–11, 43.
 
5. Bussone G, Mouthon L. Autoimmune manifestations in primary immune deficiencies. Autoimmun Rev 2009;8:332–336.
 
6. Cunningham-Rundles C. Autoimmune manifestations in common variable immunodeficiency. J Clin Immunol 2008;28(suppl 1):S42–S45.
 
7. Agarwal S, Cunningham-Rundles C. Autoimmunity in common variable immunodeficiency. Curr Allergy Asthma Rep 2009;9:347–352.
 
8. Abdel-Naser MB, Wollina U, El Hefnawi MA, et al. Non-sarcoidal, non-tuberculoid granuloma in common variable immunodeficiency. J Drugs Dermatol 2006;5:370–372.
 
9. Agarwal S, Mayer L. Pathogenesis and treatment of gastrointestinal disease in antibody deficiency syndromes. J Allergy Clin Immunol 2009;124:658–664.
 
10. Chapel HM, Spickett GP, Ericson D, et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000;20:94–100.
 
11. Moore ML, Quinn JM. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century. Ann Allergy Asthma Immunol 2008;101:114–121; quiz 122–113, 178.
 
12. Eijkhout HW, van den Broek PJ, van der Meer JW. Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Neth J Med 2003;61:213–217.
 
13. Quinti I, Soresina A, Agostini C, et al. Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration. J Clin Immunol 2008;28:263–267.
 
14. Horn J, Thon V, Bartonkova D, et al. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin Immunol 2007;122:156–162.
 
15. Gardulf A, Andersen V, Bjorkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995;345:365–369.
 
16. Berger M, Bergman GE, Murphy E, et al. Improved quality of life, IgG levels, and infection rates in patients with primary immunodeficiency disease during self-treatment with subcutaneous IgG. South Med J 2010;103:856–863.
 
17. Quinti I, Pierdominici M, Marziali M, et al. European surveillance of immunoglobulin safety—results of initial survey of 1243 patients with primary immunodeficiencies in 16 countries. Clin Immunol 2002;104:231–236.
 
18. Gardulf A, Bjorvell H, Gustafson R, et al. The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol 1993;92:200–204.
 
19. Gardulf A, Bjorvell H, Andersen V, et al. Lifelong treatment with gammaglobulin for primary antibody deficiencies: the patients' experiences of subcutaneous self-infusions and home therapy. J Adv Nurs 1995;21:917–927.
 
20. Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol 2006;6:434–442.
 
21. Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies—a prospective, multi-national study. J Clin Immunol 2006;26:177–185.
 
22. Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006;26:65–72.
 
23. Hogy B, Keinecke HO, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance .Eur J Health Econ 2005;6:24–29.